Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study

MLA

Stefano Spada, et al. “Once-Weekly Carfilzomib, Pomalidomide, and Low-Dose Dexamethasone for Relapsed/Refractory Myeloma: A Phase I/II Study.” Leukemia, vol. 32, no. 8, Nov. 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d78cb78f6d3a5917a37eca2f9e43f6af&authtype=sso&custid=ns315887.

APA

Stefano Spada, Mario Boccadoro, Roberto Mina, Angelo Belotti, Giuseppe Rossi, Lorenzo De Paoli, Rossella Troia, Antonio Palumbo, Alessandra Lombardo, Anna Marina Liberati, Sara Bringhen, Anna Maria Cafro, Pieter Sonneveld, Francesca Patriarca, Renato Fanin, Gianluca Gaidano, & Paola Bertazzoni. (2017). Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. Leukemia, 32(8).

Chicago

Stefano Spada, Mario Boccadoro, Roberto Mina, Angelo Belotti, Giuseppe Rossi, Lorenzo De Paoli, Rossella Troia, et al. 2017. “Once-Weekly Carfilzomib, Pomalidomide, and Low-Dose Dexamethasone for Relapsed/Refractory Myeloma: A Phase I/II Study.” Leukemia 32 (8). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d78cb78f6d3a5917a37eca2f9e43f6af&authtype=sso&custid=ns315887.